Short Interest in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Expands By 762.1%

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) saw a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,457 shares, a growth of 762.1% from the April 30th total of 169 shares. Based on an average daily trading volume, of 4,944 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the shares of the company are sold short.

Invesco Biotechnology & Genome ETF Price Performance

Invesco Biotechnology & Genome ETF stock opened at $82.89 on Thursday. Invesco Biotechnology & Genome ETF has a one year low of $62.25 and a one year high of $85.73. The stock has a market capitalization of $257.79 million, a PE ratio of 20.44 and a beta of 0.71. The business’s fifty day moving average is $80.06 and its 200 day moving average is $80.85.

Institutional Investors Weigh In On Invesco Biotechnology & Genome ETF

Several institutional investors have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. boosted its position in shares of Invesco Biotechnology & Genome ETF by 9,169.5% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 342,971 shares of the company’s stock valued at $28,175,000 after buying an additional 339,271 shares during the last quarter. LPL Financial LLC boosted its position in shares of Invesco Biotechnology & Genome ETF by 5.0% during the fourth quarter. LPL Financial LLC now owns 97,304 shares of the company’s stock valued at $7,994,000 after buying an additional 4,617 shares during the last quarter. United Capital Financial Advisors LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter valued at $5,946,000. Royal Bank of Canada boosted its position in shares of Invesco Biotechnology & Genome ETF by 22.3% during the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock valued at $4,783,000 after buying an additional 13,767 shares during the last quarter. Finally, Bank of America Corp DE boosted its position in shares of Invesco Biotechnology & Genome ETF by 2.5% during the third quarter. Bank of America Corp DE now owns 59,918 shares of the company’s stock valued at $4,186,000 after buying an additional 1,453 shares during the last quarter.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.